- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
Granules India Ltd and its subsidiaries are primarily involved in the manufacturing and selling of Active Pharma Ingredients (APIs), Pharmaceutical Formulation Intermediates (PFIs) and Finished Dosages.
Granules India Limited reported a strong Q1 FY27, with revenue up 22% YoY to INR1,477 Cr. EBITDA grew 37% to INR338.9 Cr (22.9% margin), and PAT surged 60% to INR180 Cr. Gross margin remained healthy at 65.6%. Net debt significantly reduced to INR101.2 Cr, and operating cash generation was robust...